To Reveal the Predictive Value of Preoperative Hemogram Parameters and BRAF Molecular Test in Predicting Malignancy in Cases With Thyroid Nodules Detected by Bethesda 3 Cytology.
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The main hypothesis of this study is that preoperative hemogram parameters can be used as biomarkers for malignancy in patients with thyroid nodule Bethesda 3 cytology. The secondary hypothesis is that BRAF molecular testing has a high predictive value in predicting malignancy in patients with thyroid nodule Bethesda 3 cytology. Primary outcome: Preoperative hemogram parameters. Secondary outcome: BRAF positivity.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: t
View:
• Patients between the ages of 18 -75
• Patients who were diagnosed with Bethesda III as a result of preoperative FNAC and decided to undergo thyroidectomy
Locations
Other Locations
Turkey
Prof. Dr. Cemil Tascioglu City Hospital
RECRUITING
Istanbul
Contact Information
Primary
Ugur 1 Kesici, Assoc. Prof.
ugur.kesici@sbu.edu.tr
00905445474710
Backup
Ugur 1 Kesici, Assoc. Prof.
ugurkesici77@mynet.com
00905445474710
Time Frame
Start Date: 2024-07-20
Estimated Completion Date: 2024-08-15
Participants
Target number of participants: 120
Treatments
2/Group B (Benign), Group M (Malign)
Mean Platelet Volume (MPV), Neutrophil/lymphocyte Ratio (NLR), Platelet/Lymphocyte Ratio (PLR) and Lymphocyte/Monocyte Ratio (LMR) will be recorded in preoperative hemograms. Among the patients included in the study, BRAF molecular testing will be performed on the preoperative cytology of 25 patients whose thyroidectomy materials were reported to be malignant. with thyroid nodule identified by Bethesda 3 cytology were examined retrospectively. According to the pathology results, they were divided into 2 groups: benign and malignant.~Group B (Benign);Preoperative hemogram parameters, Bethesda 3 cytology, Thyroidectomy, benign pathology.~Group M (Malign);Preoperative hemogram parameters, Betheda 3 cytology, Thyroidectomy, malign pathology, BRAF molecular test
Related Therapeutic Areas
Sponsors
Leads: Saglik Bilimleri Universitesi